Plus Therapeutics announced positive Phase 1 clinical trial results for Rhenium (¹⁸⁶Re) Obisbemeda in treating recurrent glioblastoma (GBM), published in Nature Communications. The therapy demonstrated safety, tumor response, and potential efficacy, with a median overall survival of 17 months for patients receiving >100 Gy, more than double the standard of care’s 8-month median survival. The findings support the ongoing Phase 2 ReSPECT-GBM trial.
This news holds substantial promise for GBM patients, a population facing a devastating prognosis with limited effective treatment options. The significant improvement in overall survival observed in the Phase 1 trial, especially for those receiving higher doses, suggests Rhenium (¹⁸⁶Re) Obisbemeda could become a valuable new therapy. The ability to deliver high radiation doses directly to the tumor without significant toxicity represents a crucial advancement in treating this aggressive cancer. This targeted approach addresses a critical unmet need in recurrent GBM, where current treatments offer marginal benefit and significant side effects.
In the Phase 1 trial, 21 patients received varying doses of Rhenium (¹⁸⁶Re) Obisbemeda, with no dose-limiting toxicity observed. The median overall survival was 11 months, exceeding the standard of care. Critically, patients receiving >100 Gy (n=12) achieved a median overall survival of 17 months compared to 6 months for those receiving <100 Gy (n=9). Tumor radiation doses reached as high as 739.5 Gy without significant toxicity, exceeding levels achievable with external beam radiation therapy. These positive Phase 1 results and the ongoing Phase 2 trial signify a potential turning point in GBM treatment. If the Phase 2 trial confirms these findings, Rhenium (¹⁸⁶Re) Obisbemeda could become a standard treatment option, offering patients a significantly improved chance of survival and potentially altering the treatment landscape for this challenging cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
